---
title: "方達控股目標業務出售予Charles River Laboratories — DecisionGateway"
description: "方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories，作為其私有化及業務分拆的一部分，讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。"
canonical_url: "https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b"
meta:
  "og:description": "方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories，作為其私有化及業務分拆的一部分，讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。"
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "方達控股目標業務出售予Charles River Laboratories — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

**Decision**/Conclude agreement

**Proposed**

# **方達控股目標業務出售予Charles River Laboratories**

方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories，作為其私有化及業務分拆的一部分，讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。

Trajectories

Sign-in readers can mine up to three arcs for this record.

[**Sign in to get trajectories **](https://dgw.tmarket.io/login?redirect=/decisions/01a1e751-2fa9-71c4-8836-866edb88173b)

## **Actors and targets**

[泰格醫藥proposer](https://dgw.tmarket.io/actors/01a1e74c-c1d4-74f0-a4bb-31f76c0ac7aa)

Targets [Charles River Laboratoriesactor](https://dgw.tmarket.io/actors/01a1e74c-c1f1-7bdf-a17b-b77b1078c399)生物分析及藥物代謝動力學(DMPK)等目標業務item

[**泰格醫藥 dossier **](https://dgw.tmarket.io/actors/01a1e74c-c1d4-74f0-a4bb-31f76c0ac7aa)

## **Source**

> 生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories，初步估值約4.7億美元

*stockintelligencenews · Telegram [ Open post](https://t.me/stockintelligencenews/5715728)*

## **Not established**

- Announcement date
- Expected closing date
- Transaction currency of payment
- Financing structure

## **Extracted detail**

## **Related decisions**

Same kind only, ranked by embedding similarity to this record.

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b#webpage","@type":"WebPage","description":"方達控股的生物分析及DMPK等目標業務將以約4.7億美元初步估值出售予Charles River Laboratories，作為其私有化及業務分拆的一部分，讓泰格醫藥剝離非核心業務並聚焦臨床CRO服務。","name":"方達控股目標業務出售予Charles River Laboratories — DecisionGateway","url":"https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b","breadcrumb":{"@id":"https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/decisions/01a1e751-2fa9-71c4-8836-866edb88173b#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Feed","item":"https://dgw.tmarket.io/feed","position":2},{"@type":"ListItem","name":"方達控股目標業務出售予Charles River Laboratories","position":3}]}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
